Deutsche Bank Ag\ Allovir, Inc. Transaction History

Deutsche Bank Ag\

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$0.64 - $0.78 $31,460 - $38,342	49,157 Added 227.64%	70,751 $53,000
Q2 2023 Aug 14, 2023	BUY	$3.17 - $5.82 $5,769 - $10,592	1,820 Added 9.2%	21,594 $73,000
Q1 2023 May 15, 2023	BUY	$3.94 - $7.05 $19,719 - $35,285	5,005 Added 33.89%	19,774 $77,000
Q4 2022 Feb 13, 2023	BUY	$4.7 - $9.98 $977 - $2,075	208 Added 1.43%	14,769 $75,000
Q3 2022 Nov 14, 2022	SELL	$4.13 - $8.79 $11,935 - $25,403	-2,890 Reduced 16.56%	14,561 $115,000
Q2 2022 Aug 11, 2022	SELL	$3.26 - $7.06 $26,164 - $56,663	-8,026 Reduced 31.5%	17,451 $69,000
Q1 2022 May 13, 2022	SELL	$6.75 - $13.52 $6,061 - $12,140	-898 Reduced 3.4%	25,477 $172,000
Q4 2021 Feb 11, 2022	SELL	$12.94 - $25.99 $19,940 - $40,050	-1,541 Reduced 5.52%	26,375 $342,000
Q3 2021 Nov 04, 2021	BUY	$16.97 - $25.06 $51,758 - $76,433	3,050 Added 12.27%	27,916 $700,000
Q2 2021 Aug 11, 2021	SELL	$19.44 - $25.06 $26,399 - $34,031	-1,358 Reduced 5.18%	24,866 $491,000
Q1 2021 May 13, 2021	BUY	$20.81 - $45.5 $157,469 - $344,298	7,567 Added 40.56%	26,224 $613,000
Q4 2020 Feb 16, 2021	BUY	$23.94 - $46.81 $157,333 - $307,635	6,572 Added 54.38%	18,657 $717,000
Q3 2020 Nov 12, 2020	BUY	$21.05 - $42.7 $254,389 - $516,029	12,085 New	12,085 $332,000

44.6M

14.9K

200

Ticker ALVR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,063,400
Market Cap $51.2M
Description
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, ...

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

Stay updated on Deutsche Bank Ag\ with notifications on news.